An FDA inspection raises questions about Bristol Myers Squibb's liso-cel facility and the CVR, but analysts urge caution

For months, speculation over Bristol Myers Squibb and its $9 Celgene CVR has focused on whether the FDA would be able to inspect the Big Pharma’s cell therapy plant in Texas in time to approve their ‘liso-cel’ cancer therapy. But on Friday, the agency posted a document to its website announcing that it had looked at the company’s other liso-cel plant in Washington and found problems there, including over sterilization procedures.